As the most potent CELMoD, mezigdomide results in the rapid degradation of Ikaros and Aiolos substrate proteins and induction of apoptosis in MM cells, together with strong stimulation of the immune system, and thus has a differentiated preclinical profile compared to the IMiD compounds. Here, IKZF3 is linked to Miyoshi myopathy.